RxDoctor Payments Data

Andy Kuo-Chen Hu, MD

Internal Medicine · Brooklyn, NYNPI 1942276530

Payments from drug & device makers

$2,598in general payments, 2019–2025

Across 28 payments — averaging $92.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$413
  • GSK$371
  • AstraZeneca$278
  • Johnson & Johnson$250
  • Gilead$217
  • AbbVie$166
  • plus $904 from 8 others

What the payments were for

  • Food & beverage$2,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,598 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$32,354
Medicare patients
32
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl1,027$379,602
FarxigaDapagliflozin Propanediol398$265,631
JardianceEmpagliflozin397$243,933
JanumetSitagliptin Phos/Metformin Hcl259$152,011
Diclofenac Epolamine185$126,878
LinzessLinaclotide130$68,685
JentaduetoLinagliptin/Metformin Hcl108$65,152
EliquisApixaban100$64,690
TrulicityDulaglutide55$63,046
ProliaDenosumab32$52,853
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$48,149
TradjentaLinagliptin80$47,191
JanuviaSitagliptin Phosphate70$42,768
Diclofenac Sodium172$42,090
MyrbetriqMirabegron69$31,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto, Tradjenta, Combivent Respimat$144$366,747608 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$278$323,034506 claims
AbbVieLinzess, Creon, Restasis$166$127,889204 claims
Lilly USA, LLCTrulicity$124$63,04655 claims
Johnson & JohnsonXarelto$250$26,67845 claims
GSKBreo Ellipta$371$7,36720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →